Bounc­ing back from a shock­ing CRL, Athenex shares soar with buy­out of nat­ur­al killer T cell play­er

5 years ago
Deals

Is that an­oth­er IPO in the mak­ing? Ex-No­var­tis CEO Joe Jimenez and a lead Kite play­er take up new posts at an ...

5 years ago
People

Clo­vis spikes ovar­i­an can­cer com­bo af­ter 'un­der­whelm­ing' ef­fi­ca­cy; Servi­er wins pri­or­i­ty re­view for Tib­so­vo ex­pan­sion

5 years ago
News Briefing

An em­ploy­ee com­plaint at Eli Lil­ly's Branch­burg plant al­leges al­tered qual­i­ty con­trol docs amid FDA probe — re­port

5 years ago
Pharma
Coronavirus

A biotech with a yen for pricey rare dis­ease drugs — and bar­gain base­ment shop­ping — adopts an­oth­er or­phan in ...

5 years ago
Deals

Opin­ion: Waiv­ing Covid-19 vac­cine IP could save lives, but where is the man­u­fac­tur­ing ca­pac­i­ty?

5 years ago
FDA+
Opinion

Ada­gio of­fers first peek at Covid-19 an­ti­body da­ta, with pre­ven­ta­tive num­bers that may ri­val mR­NA vac­cines

5 years ago
R&D
Coronavirus

It’s a new $DAWN for Day One as start­up piv­ots to an IPO for more fund­ing to back its work in pe­di­atric can­cer

5 years ago
Financing

Start­up sets out to tack­le the gene ther­a­py man­u­fac­tur­ing cri­sis

5 years ago
Financing
Startups

Chemo­Cen­tryx plunges as FDA rais­es ques­tions about rare dis­ease drug ahead of ad­comm

5 years ago
Pharma
FDA+

Vik Ba­ja­j's start­up in­cu­ba­tor at Fore­site un­cloaks an im­munol­o­gy play­er with a lead TYK2 in­hibitor in tow

5 years ago
Financing
Startups

'Chang­ing the whole game of drug dis­cov­ery': Leg­endary R&D vet Roger Perl­mut­ter leaps back in­to work as a biotech CEO

5 years ago
People
Startups

Fo­cused on the cell ther­a­py man­u­fac­tur­ing bot­tle­neck, Cel­lares tur­bocharges plans for 'shut­tle' tech

5 years ago
Financing
Cell/Gene Tx

Gene ther­a­pies in the knee? With the help of a small herd of hors­es, a new start­up hopes to crack os­teoarthri­tis

5 years ago
Startups
Cell/Gene Tx

An­drew Radin or­ches­trates his AI dis­cov­ery plat­for­m's piv­ot to R&D with a har­mo­nious name change and eyes on the ...

5 years ago
AI

Lon­nie Moul­der woos a sea­soned de­vel­op­ment ex­pert from Hill­house­'s US/Chi­na play to helm his start­up

5 years ago
People

A UK-based start­up looks to beat Spark's Lux­tur­na at its own game with pro­gram­ma­ble cell plat­form for eye dis­ease

5 years ago
Financing

Se­quenc­ing up­start rais­es $273M ahead of IPO; Ac­er­a­gen ac­quires high­ly-an­tic­i­pat­ed Far­ber dis­ease treat­ment

5 years ago
News Briefing

Mer­ck lays out vi­sion for wom­en's health spin­out Organon, with some spe­cial plans for its $9B wind­fall

5 years ago
Pharma

Re­searchers are look­ing to solve PTSD. Could MD­MA-as­sist­ed ther­a­pies pro­vide an an­swer?

5 years ago
R&D

Re­gen­eron’s gold­en goose Eylea may stave off biosim­i­lar com­pe­ti­tion un­til 2024 or be­yond

5 years ago
Pharma

Josh Bilenker and Jeff En­gel­man bun­dle a moth­er lode of cash for their stealthy start­up, at­tract­ing a who's who of ...

5 years ago
Startups
Bioregnum

Can a top­i­cal treat­ment beat block­buster eye in­jecta­bles? A Swiss biotech has the cash now to find out

5 years ago
Financing

How much? Pfiz­er ex­pects to reap at least $26B from Covid vac­cine in 2021

5 years ago
R&D
Coronavirus
First page Previous page 708709710711712713714 Next page Last page
A service from the Financial Times